United Kingdom Ulcerative Colitis Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressants, Calcineurin Inhibitors, and Others), By Disease Type (Proctosigmoiditis, Ulcerative Proctitis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), and United Kingdom Ulcerative Colitis Market Insights, Industry Trend, Forecasts to 2033

United Kingdom Ulcerative Colitis Market Insights Forecasts to 2033

• The United Kingdom Ulcerative Colitis Market Size was valued at USD 407.5 Million in 2023.
• The United Kingdom Ulcerative Colitis Market Size is Growing at a CAGR of 3.57% during the forecast period 2023 to 2033
• The United Kingdom Ulcerative Colitis Market Size is anticipated to reach USD 578.5 Million by 2033

The United Kingdom Ulcerative Colitis Market Size is anticipated to Exceed USD 578.5 Million by 2033, Growing at a CAGR of 3.57% from 2023 to 2033. The rising prevalence of ulcerative colitis and growing research & development activities are driving the growth of the ulcerative colitis market in the UK.     

Market Overview

The ulcerative colitis market refers to the industry providing treatments for ulcerative colitis, which is a chronic inflammatory bowel disease. It includes various drug classes, including aminosalicylates, steroids, immunomodulators, and biologics, as well as devices, diagnostics, and other products related to UC management. Ulcerative colitis is characterized by the inflammation and ulcers in the inner lining of the large intestine (colon) and rectum. The increasing prevalence of ulcerative colitis, owing to factors like urbanization, changes in diet, and environmental factors, is responsible for propelling the market. Further, the awareness about the early diagnosis and treatment of the disease, driving demand for medical therapies, ultimately results in escalating the market demand for ulcerative colitis. Advances in treatment options, including biologics, advances in imaging, endoscopy, and biomarkers for improving the early diagnosis and treatment initiation for better management of ulcerative colitis, are escalating the market growth opportunities.

Report Coverage

This research report categorizes the market for the UK ulcerative colitis market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom ulcerative colitis market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the UK ulcerative colitis market.

Driving Factors

The rising prevalence of ulcerative colitis in the country is responsible for driving the market demand. 1 in every 227 people in the UK is estimated to be diagnosed with ulcerative colitis, which amounts to around 296,000 people. The UK government committed to increasing public investment and fostering a strong research and innovation ecosystem. Thus, the increasing research and development activities are significantly contributing to propelling the market growth. 

Restraining Factors

The increased treatment costs, as well as side effects & safety concerns associated with ulcerative colitis treatment, are challenging the market growth.

Market Segmentation

The United Kingdom Ulcerative Colitis Market share is classified into drug type and disease type.

• The calcineurin inhibitors segment dominated the market with the largest market share in 2023 and is expected to grow at a significant CAGR during the projected period.

The United Kingdom ulcerative colitis market is segmented by drug type into anti-inflammatory drugs, anti-TNF biologics, immunosuppressants, calcineurin inhibitors, and others. Among these, the calcineurin inhibitors segment dominated the market with the largest market share in 2023 and is expected to grow at a significant CAGR during the projected period. Calcineurin inhibitors, such as cyclosporine and tacrolimus, are used to induce remission in steroid-refractory ulcerative colitis (UC). The efficiency of these drugs for managing moderate to severe cases of ulcerative colitis is driving the market growth.

• The proctosigmoiditis segment dominated the United Kingdom ulcerative colitis market in 2023 and is expected to grow at a significant CAGR during the projected period.

The United Kingdom ulcerative colitis market is segmented by disease type into proctosigmoiditis, ulcerative proctitis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Among these, the proctosigmoiditis segment dominated the United Kingdom ulcerative colitis market in 2023 and is expected to grow at a significant CAGR during the projected period. Proctosigmoiditis is a chronic inflammatory bowel disease affecting the large intestine, characterized by inflammation and ulcers in the rectum and sigmoidal colon. The growing prevalence of proctosigmoiditis, as well as demand for novel & effective treatment, is responsible for propelling the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.K. ulcerative colitis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie Inc. (Allergan, Inc.)
• Merck & Co., Inc.
• Novartis AG
• Bausch Health Companies Inc.
• Johnson & Johnson
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2024, NICE recommended a new drug for ulcerative colitis that could benefit 25,000 patients. Etrasimod is offered to patients aged over 16 years, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or biological treatment for moderately to severely active ulcerative colitis.

Market Segment

This study forecasts revenue at U.K., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United Kingdom Ulcerative Colitis Market based on the below-mentioned segments:

UK Ulcerative Colitis Market, By Drug Type

• Anti-Inflammatory Drugs
• Anti-TNF biologics
• Immunosuppressants
• Calcineurin Inhibitors
• Others

UK Ulcerative Colitis Market, By Disease Type

• Proctosigmoiditis
• Ulcerative Proctitis
• Left-sided Colitis
• Pancolitis or Universal Colitis
• Fulminant Colitis